Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817113 | 1.00 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL17320112 | 1.00 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL28107477 | 0.99 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL28107109 | 0.89 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL7314623 | 0.89 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL27852999 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EGAA | |
| SCHEMBL2032041 | 0.84 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2SIGMAR1KDM4ECYP1A2 | |
| SCHEMBL21618307 | 0.84 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2SIGMAR1KDM4ECYP1A2 | |
| SCHEMBL1818801 | 0.84 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2SIGMAR1KDM4ECYP1A2 | |
| SCHEMBL2029008 | 0.83 | MAOA (0.60) | ALDH1A1SMN1; SMN2SIGMAR1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268641-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Pvt. Ltd. (IN) | 2011-01-05 | — | — | EP | claimed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527884-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038653-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | McKee, Patrick A. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| CN-101123962-A | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | ALDH1A1 2795/4885SMN1; SMN2 4446/4885SIGMAR1 1123/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | ALDH1A1 749/4885SMN1; SMN2 3352/4885SIGMAR1 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.